ProFactor Pharma LTD
  • Home
  • About Us
  • Haemophilia
  • Technology
  • Team
  • Contact
  • News
Select Page

ProFactor Pharma Ltd. secures funding to develop a novel enhanced half-life recombinant human Factor VIII

by Richard Cruse | Feb 6, 2025 | Press releases

ProFactor Pharma Ltd. (PFP), a UK biotech company, is pleased to announce it has been awarded a SMART: SCOTLAND grant from Scottish Enterprise. This grant has been awarded to perform a preclinical Proof-of-Concept study of a novel approach to significantly improve the...

Articles

  • ProFactor Pharma Ltd. secures funding to develop a novel enhanced half-life recombinant human Factor VIII February 6, 2025
  • World Hemophilia Day April 11, 2024
  • Eugenia Wachters appointed Chief Operating Officer at ProFactor Pharma July 10, 2023
  • World Hemophilia Day April 19, 2023
  • ProFactor Pharma (PFP) realise further capital injection – August 2022 September 20, 2022
  • Health Tech World – Interview – Ending the Haemophilia Drug Shortage (23 November 2021) November 24, 2021
  • Profactor Pharma Announces Issuance of Indian and Eurasian Patent Covering a high yielding cell line for treatment of Haemophilia A March 31, 2021
  • Profactor Pharma completes optimisation of process for manufacture of lowest cost recombinant FVIII January 31, 2021
  • World-wide inequalities in Haemophilia care. Things are getting better? January 19, 2021
  • Outstanding technical progress July 15, 2020
  • Home
  • About Us
  • Haemophilia
  • Technology
  • Team
  • Contact
  • News